TES Pharma Congratulates Intercept Pharmaceuticals on their Pr...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
PERUGIA, Italy, Nov. 9, 2022, /PRNewswire-AsiaNet/-- INT-787 is a selective next generation FXR agonist invented by TES Pharma and licensed to Intercept PharmaceuticalsINT-787 has shown strong anti-fibrotic and anti-inflammatory effects in animal modelsTES Pharma is dedicated to the identifi...
Authors: LATEST ASIANET NEWS RELEASES